Myocardial Solutions, Inc. (MSI) announced FDA 510(k) clearance for MSI’s MyoStrain diagnostic software, providing a new, rapid, accurate, and safe segmental strain test for quantifying subclinical cardiac dysfunction. MyoStrain quantifies cardiac contraction across 48 segments of the heart in a...
Nine different abstracts utilizing Myocardial Solutions’ MyoStrain® were presented at Society for Cardiovascular Magnetic Resonance (SCMR) 2019 22nd Annual Scientific Sessions in Bellevue, Washington on February 6th-9th, 2019. The papers span a variety of subjects including MyoStrain...
The Journal of Medical Economics published a manuscript authored by Avalon Health Economics (Avalon) that demonstrates the significant cost savings that could be achieved by using MyoStrain to diagnose coronary artery disease (CAD). The article compares MyoStrain to the current standard of care...
A series of three abstracts utilizing MyoStrain®, Myocardial Solutions’ patented technology, were accepted and presented at American Heart Association (AHA) 2018 Scientific Sessions on November 10-12, 2018. The abstracts were based on studies conducted at Sharon Regional Medical Center in Sharon...
Dr. Henning Steen (Marien Hospital; Hamburg, Germany) presented his “10 Good Reasons to Use MyoStrain” at the Global Cardio-Oncology Summit 2018 in Tampa, Florida on September 27th. Dr. Steen has used Myocardial Solutions’ MyoStrain technology for cardiac MR (“CMR”) strain imaging in multiple...
